National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 10/16/2007     First Published: 7/1/2001  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Colorectal Cancer Drugs Require Careful Patient Selection

Cetuximab for Advanced Lung Cancer

Past Highlights
Phase II Randomized Study of the Effects of a Low Fat, High Fiber Diet on Serum Factors in Patients With Prostate Cancer

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information
Registry Information

Alternate Title

Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II


Prevention


Closed


40 to 80


NCI


UCLA-0001030
NCI-G01-1973, NCT00020995

Objectives

  1. Compare the inhibition of growth of human prostate cancer cell lines by serum from patients with prostate cancer before and after being fed a low fat, high fiber diet.
  2. Determine the underlying mechanism through which a low fat, high fiber diet affects the growth of prostate cancer cell lines.
  3. Determine whether a low fat, high fiber diet inhibits the growth of prostate cancer cell lines through androgen-dependent and/or androgen- independent mechanisms in these patients.
  4. Determine the growth factors, hormones, and/or binding proteins that may be responsible for affecting the growth of prostate cancer cell lines in these patients.

Entry Criteria

Disease Characteristics:

  • Diagnosis of adenocarcinoma of the prostate


  • Previously untreated and on watchful waiting


  • Medically able to receive dietary intervention


Prior/Concurrent Therapy:

Biologic therapy:

  • Not specified

Chemotherapy:

  • Not specified

Endocrine therapy:

  • No concurrent luteinizing hormone-releasing hormone agonists (leuprolide or goserelin)
  • No concurrent androgen-receptor blocking agents (flutamide or bicalutamide)
  • No concurrent testosterone
  • No concurrent insulin
  • No concurrent finasteride

Radiotherapy:

  • Not specified

Surgery:

  • No prior orchiectomy

Other:

  • No concurrent saw palmetto supplement

Patient Characteristics:

Age:

  • 40 to 80

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Not specified

Renal:

  • Not specified

Other:

  • Must be willing to travel to UCLA 3 days a week for 4 weeks to obtain specially prepared foods

Expected Enrollment

A total of 40 patients (20 per arm) will be accrued for this study within 6 months.

Outline

This is a randomized study. Patients are randomized to 1 of 2 arms.

  • Arm I: Patients receive a low fat, high fiber diet daily for 3 weeks.


  • Arm II: Patients receive a control diet containing the standard amounts of fat and fiber.


Trial Contact Information

Trial Lead Organizations

Jonsson Comprehensive Cancer Center at UCLA

William Aronson, MD, Protocol chair
Ph: 310-268-3446; 888-798-0719

Registry Information
Official Title Effects of a Low Fat Diet on Serum Factors and Prostate Cancer
Trial Start Date 2001-08-09
Registered in ClinicalTrials.gov NCT00020995
Date Submitted to PDQ 2001-05-11
Information Last Verified 2004-05-18
NCI Grant/Contract Number P30-CA16042

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.


Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov